| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -132,431 | -49,198 |
| Stock-based compensation expense | 7,867 | 4,696 |
| Non-cash operating lease expense | 945 | 619 |
| Loss on assignment of finance lease | 158 | 158 |
| Depreciation and amortization | 91 | 63 |
| Amortization of finance lease right-of-use asset | 13 | 13 |
| Non-cash interest expense | 7 | 7 |
| Gain on disposal of property and equipment | 48 | 48 |
| Accretion of discounts, net of amortization of premiums, on available-for-sale investments | 166 | - |
| Reversal due to settlement of indirect tax liabilities | -9,445 | -9,445 |
| Loss on disposal of discontinued operations | 0 | 0 |
| Amortization of costs to obtain a contract with a customer | 0 | 0 |
| Accounts receivable | 167 | 165 |
| Inventory | 0 | 0 |
| Prepaid expenses, other current assets, and other assets | 25,177 | 206 |
| Accounts payable and accrued liabilities | 58,745 | -4,819 |
| Accrued indirect tax liabilities | -1,527 | -1,665 |
| Accrued compensation and benefits | -1,373 | -2,252 |
| Contract liabilities | 0 | 0 |
| Operating lease liabilities | -1,018 | -669 |
| Net cash used in operating activities | -103,526 | -62,911 |
| Purchases of available-for-sale investments | 176,470 | - |
| Proceeds from sales of property and equipment | 185 | 185 |
| Purchases of property and equipment | 0 | 0 |
| Net cash used in investing activities | -176,285 | 185 |
| Proceeds from underwritten public offering, net of issuance costs | 376,910 | 378,125 |
| Proceeds from at-the-market offering of common stock, net of issuance costs | 4,121 | 4,126 |
| Proceeds from exercise of stock options | 2,641 | 1,124 |
| Proceeds from private placement, net of issuance costs | 0 | 0 |
| Deferred financing costs | - | 137 |
| Payment of finance lease liabilities | 50 | 50 |
| Payment for shares withheld to fund payroll taxes | 0 | 0 |
| Net cash provided by financing activities | 383,622 | 383,462 |
| Net increase in cash, cash equivalents and restricted cash | 103,811 | 320,736 |
| Cash and cash equivalents at beginning of period | 196,177 | - |
| Cash and cash equivalents at end of period | 299,988 | - |
Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc. (CDTX)